Background & Aims: Individuals with inflammatory bowel disease (IBD) have an increased risk of herpes zoster (HZ) infection. Although the efficacy of recombinant zoster vaccine (RZV) is high among immunocompetent individuals, little is known about its effect among immunosuppressed individuals with IBD.
Methods: We conducted a retrospective cohort study among individuals in the national Veterans Affairs Healthcare System diagnosed with IBD on or before January 3, 2018, the earliest date of RZV vaccinations. We collected data on 7008 and 26,292 eligible patients with IBD in the 50- to 60-year and >60-year age groups, respectively. We identified veterans who received RZV and compared the incidence of HZ between vaccinated versus unvaccinated individuals. We performed multivariable Cox regression with time varying analysis to determine the risk of HZ among the vaccinated (full dose and single dose separately) versus unvaccinated cohort, stratified by IBD medications.
Results: The crude HZ incidence rate after full dose vaccination of RZV when compared with the unvaccinated group was lower in both the 50- to 60-year age group (0.00 vs 3.93 per 1000 person-years) and >60-year age group (1.80 vs 4.57 per 1000 person-years). RZV vaccination was associated with a significantly lower risk of HZ among the 50- to 60-year and >60-year age groups, although this was limited by low HZ event rates.
Conclusion: RZV vaccination was associated with decreased risk of HZ infection among both the 50- to 60-year and >60-year age groups. Greater efforts should be made to vaccinate all patients with IBD with RZV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2021.07.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The excess direct social cost of dementia-related neuropsychiatric symptoms: a beyond silos region-wide cohort study.
Value Health
December 2024
Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain. Electronic address:
Objectives: The objective was to estimate the excess formal social costs or direct non-healthcare costs of dementia-related neuropsychiatric symptoms (NPS).
Methods: The presence of dementia, NPS, antipsychotic and/or antidepressant use, somatic and psychiatric comorbidities, and formal social benefits were studied in a region-wide cohort of all over-60-year-olds. A random forest-based algorithm identified NPS and two-part regression models and entropy balance were used.
Successful management of immunotherapy-resistant respiratory failure in anti-mitochondrial M2 antibody-positive myositis by modified lung volume recruitment therapy: A case report.
Medicine (Baltimore)
December 2024
Department of Neurology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
Rationale: Anti-mitochondrial antibodies (AMA) M2-positive myositis can lead to severe respiratory failure. Traditional immunotherapies sometimes fail to address respiratory failure. Herein, this CARE-compliant case report described a patient with AMA-M2-positive myositis who recovered from ventilation with tracheostomy owing to immunotherapy-resistant respiratory failure to spontaneous breathing after modified lung volume recruitment (mLVR) therapy.
View Article and Find Full Text PDFAnti-LGI1 Autoimmune Limbic Encephalitis: An Easy-To-Miss Diagnosis.
Eur J Case Rep Intern Med
November 2024
Internal Medicine Department, Hospital Central do Funchal, Funchal, Portugal.
Background: Autoimmune limbic encephalitis (ALE) is a rare inflammatory disorder characterised by a subacute onset, usually within weeks. The presence of multiple neuropsychiatric symptoms such as seizures, short-term memory deficits, anxiety and depression often leads to misdiagnosis as another medical condition, contributing to poor prognosis and reduced long-term survival.
Case Description: A 60-year-old man, with no chronic illnesses, presented at the emergency department with daily episodes of palpitations, shivering, piloerection and a sense of impending doom lasting two months.
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring Class 3 Mutations.
JCO Precis Oncol
December 2024
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Article Synopsis
- * In a study at an institution, two patients with class 3-mutated NSCLC showed significant responses to the EGFR tyrosine kinase inhibitor erlotinib after previous treatments failed; one achieved complete response and the other had a partial response.
- * Research indicated that class 3-mutated NSCLC cell lines demonstrated sensitivity to EGFR-TKIs at lower concentrations compared to class 1 and 2 mutations, suggesting that class 3 mutations could represent a new targetable group for treatment.
First Successful In-Human Application of 225Ac-DOTA-LM3 Mono-PRRT for the Treatment of an Otherwise Therapy-Resistant Neuroendocrine Tumor (NET G3).
Clin Nucl Med
January 2025
From the Department of Nuclear Medicine, Saarland University, Homburg, Germany.
Article Synopsis
- A 60-year-old woman was diagnosed with advanced small bowel neuroendocrine tumor (NET G3) that had spread to the liver and was showing aggressive metabolic activity.
- After initial treatment with chemotherapy, her disease progressed, leading to the use of targeted therapy called PRRT, combining 177Lu-DOTA-octreotate and 225Ac-DOTA-octreotate, which stabilized her condition.
- A novel treatment with 225Ac-DOTA-LM3, a somatostatin receptor antagonist, resulted in an improved treatment response, marking the first documented evidence that this approach may be more effective than standard treatments for this type of cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!